-

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (NASDAQ: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 12, 2023 and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit http://www.virtualshareholdermeeting.com/AGEN2023 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:
Date: Monday, June 12, 2023
Time: 10:30 a.m. ET

A live webcast and replay will be accessible from the Company's website at https://investor.agenusbio.com/events-and-presentations and at http://www.virtualshareholdermeeting.com/AGEN2023.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on developing therapies that engage the body's immune system in fighting cancer and infections. The Company's mission is to broaden the patient populations benefiting from cancer immunotherapy through combination approaches, leveraging a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio.

Information that may be important to investors will be routinely posted on our website and Twitter.

Contacts

Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com

Industry:

Agenus

NASDAQ:AGEN
Release Versions
English

Contacts

Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com

More News From Agenus

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical insights, and the evolving treatment landscape for colorectal cancer. The session will be moderated by Garo Armen, PhD, Fo...

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France’s Autorisation d’Accès Compassionnel (...

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory Fr...
Back to Newsroom